The decision is made in agreement with Per Norlén and is part of the review of the company that takes place after the negative initial result in the phase 2 NeoFox study.

Norlén will continue to work as CEO during the notice period that ends on April 9, 2025.

In order to create the best possible value for the shareholders, talks are ongoing with other companies regarding the possibility of carrying out a merger or a reverse acquisition.

WntResearch announced in September 2024 that the clinical phase 2 study NeoFox did not show any clinically significant effects on tumor size or lymph nodes and the company decided to end the study and begin work to reduce costs and take advantage of the values ​​remaining in the company. In order to create the best possible value for the shareholders, talks are ongoing with other companies regarding the possibility of carrying out a merger or a reverse acquisition. In addition, discussions are ongoing with the aim of realizing the remaining value of the medicinal substance and the patent portfolio. In parallel with this work, the CEO and board have jointly identified the opportunity to further reduce the cost base by terminating Per Norlén’s employment as CEO.